Global digital health innovator Qure.ai has been awarded a multimillion-dollar grant from the Bill & Melinda Gates Foundation aimed at accelerating the development and deployment of cutting-edge AI diagnostics to detect tuberculosis (TB) and pneumonia early — especially in under-resourced regions where access to timely medical imaging and expert clinicians is limited.
The funding marks a major milestone for the company’s work in health equity and digital diagnostics and will support two key components of its next phase of innovation:
🧠 AI-Enabled Point-of-Care Ultrasound Algorithms
One of the principal goals of the grant is to develop AI algorithms for point-of-care ultrasound (POCUS) — portable imaging tools that can help health workers detect signs of TB and pneumonia at the frontline, without requiring specialist radiologists on site. These tools are designed to aid early diagnosis and intervention, which is critical for both conditions, particularly in low- and middle-income settings where such diseases cause the most mortality.
📊 Large Open-Source Multimodal Lung Health Database
The grant will also fund the creation of a comprehensive open-source database, aligned with World Health Organization (WHO) lung-health diagnostic pathways, to accelerate research and innovation globally. This dataset is planned to include:
- Chest X-rays
- Thoracic ultrasound images
- High-resolution CT scans
- Cough and lung sound recordings
- Associated clinical history and laboratory markers
By making this dataset publicly available (while safeguarding privacy), Qure.ai aims to enable researchers, developers, and health organizations around the world to develop and validate new AI models that can enhance disease detection and accuracy.
Why It Matters: The Global Health Impact
Both TB and pneumonia remain among the leading causes of death worldwide, despite being curable when caught early:
- Tuberculosis is estimated to cause around 1.23 million deaths annually.
- Pneumonia contributes to about 2 million deaths each year, including approximately 700,000 children under five.
In many regions with high disease burdens, access to trained clinicians, imaging facilities, and rapid diagnostic pathways is limited. Qure.ai’s approach — combining AI with portable ultrasound and large databases — has the potential to significantly reduce time to diagnosis, empower community health workers, and improve patient outcomes where healthcare resources are scarce.
Qure.ai’s AI technology already supports clinical programs across more than 105 countries and 4,800 sites worldwide, covering use cases including TB, lung cancer, and neurocritical care. This grant allows the company to extend its impact into earlier detection of infectious lung diseases and push toward broader health equity goals.
What Qure.ai Leaders Are Saying
- Prashant Warier, Founder & CEO, described the grant as a validation of Qure.ai’s mission and decades of work in delivering AI diagnostics to underserved communities.
- Dr. Shibu Vijayan, Chief Medical Officer – Global Health, highlighted the potential to reach healthcare “blind spots” with high-quality diagnostics.
- Dr. Justy Antony Chiramal, Project Lead, emphasized the need for better tools to address the high child mortality rate from pneumonia and other lung illnesses.
Broader Context: AI and Global Health Innovation
This initiative reflects a broader shift in global health funding toward AI-driven tools and open-data approaches that can be shared across research and public health communities. By building a multimodal repository and advancing point-of-care AI diagnostics, Qure.ai’s project helps bridge gaps between advanced medical imaging and frontline healthcare, especially in low-resource settings that need it most.
Investments like this also signal growing recognition among global funders that digital health technologies, including AI, will play a pivotal role in tackling preventable diseases and improving health outcomes worldwide.
